# Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)

> **NCT00393705** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 302 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Biphasic Aspart 30/70
- **DRUG:** insulin lispro LM
- **DRUG:** insulin lispro MM
- **DRUG:** insulin lispro LM

## Key facts

- **NCT ID:** NCT00393705
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2010-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00393705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00393705, "Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00393705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*